Rationale: MicroRNAs (miRNAs) destabilize mRNA transcripts and inhibit protein translation. miR-145 is of particular interest in cystic fibrosis (CF) as it has a direct binding site in the 39-untranslated region of CFTR (cystic fibrosis transmembrane conductance regulator) and is upregulated by the CF genetic modifier TGF (transforming growth factor)-b.
Cystic fibrosis (CF) is the most common monogenic fatal respiratory disease, affecting 1 in 3,500 white individuals (1, 2) . TGF (transforming growth factor)-b has been identified repeatedly as a genetic modifier of CF disease progression, with direct effects on CFTR (cystic fibrosis transmembrane conductance regulator) synthesis and function (3) (4) (5) (6) (7) (8) . We and others have identified an association between increased TGF-b and diminished CFTR transcription, protein levels, and ion channel function, suggesting a feedback loop in which increased TGF-b diminishes CFTR activity, and loss of CFTR function increases TGFb-dependent secretion and signaling (9, 10) . As TGF-b is a pluripotent regulator of cellular functions including cell differentiation, repair, and remodeling (11, 12) , it is important to ascertain the precise mechanisms by which TGF-b modifies CFTR function and CF lung disease.
MicroRNAs (miRNAs) are small (20-22 nucleotides) noncoding RNAs that may regulate more than 60% of proteincoding genes in human cells (13) (14) (15) . miRNAs have emerged as important modifiers of lung development and pulmonary fibrosis (16, 17) , modifying mRNA transcript stability and protein translation in a sequence-specific manner (18) . Candidate miRNAs have been identified that regulate CFTR expression and function (15, 19) . Among these, miR-145 is of significant interest to our group as it has a direct binding site on the 39-untranslated region (39-UTR) of the CFTR mRNA transcript (20) (21) (22) and is upregulated by TGF-b in fibrotic disease (23) . In the era of CFTR modulator development (24) (25) (26) (27) , delineating mechanistic factors that partially restore or inhibit CFTR function acquires enhanced significance for optimizing strategies for CFTR modulation. Similarly, increased awareness of acquired CFTR dysfunction (28) (29) (30) (31) in non-CF respiratory disease extends the significance of TGF-b inhibition of CFTR levels and function. In the current study, we build on the initial reports of miRNA in CF to investigate the contribution of miRNA to TGFb-associated CF lung disease and the impact on F508del CFTR corrector response. Specifically, we hypothesize that miR-145 mediates TGF-b downregulation of CFTR in airway epithelia, and conduct a series of experiments to test the benefit of miRNA antagonism to augment CFTR correction in the setting of TGF-b-associated disease. Some of these results previously have been reported in the form of abstracts presented to the North American Cystic Fibrosis Conference and American Thoracic Society international meetings (32, 33) .
Methods Cell Culture
Primary polarized non-CF and CF (homozygous F508del) human airway epithelial cells were cultured by the Gregory Fleming James Cystic Fibrosis Research Center Tissue Procurement Core at the University of Alabama at Birmingham, utilizing established techniques (27, 34, 35) . Briefly, cells were initially expanded in growth medium and then differentiated on Each data point represents summary data from three independent experiments (n = 3). (C) Expression profiles of CFTR-specific miRNAs (miR-145, miR-101, and miR-494) in non-cystic fibrosis (CF) and CF primary airway epithelial cells. Each miRNA data point represents summary data from three biological replicates (n = 3 donors). (D) Increased miR-145 in F508del CFBE cell line (n = 3). All experiments were repeated at least three times. Quantitative PCR data were analyzed by the DDC t method. Data are presented as the median of normalized expression (to U6 small nuclear RNA) with interquartile range. WT = wild type. *P , 0.05; **P , 0.01. 
At a Glance Commentary

BAL Fluid Exosomes
BAL was performed per clinical routine (36, 37) , and remnant fluid was collected and processed as previously described (38) . In brief, exosomes were isolated by differential centrifugation (300 g for 10 min, then 2000 g for 20 min, then 10,000 g for 30 min) and then pelleted at 150,000 g for 2 hours before resuspension in phosphate-buffered saline and centrifuging at 500,000 g for 15 minutes. Exosome quantification was performed with the NanoSight NS300 (Malvern Instruments), stained with Qtracker 565 (Life Technologies) and visualized with a 488-nm laser module and long-pass filter.
miRNA Isolation and qPCR Assays miRNA was isolated from cells and human BAL-derived exosomes, using an miRNeasy mini kit according to the manufacturer's instruction (Qiagen). Isolated RNAs were processed for real-time qPCR, using QIAgility robot and Rotor-Gene Q PCR cycler system (Qiagen) in accordance with the manufacturer's instructions (see www. qiagen.com). TaqMan probes for CFTR, TGF-b, PAI (plasminogen activator inhibitor)-1, BMP2 (bone morphogenetic protein 2), and LTBP2 (latent TGFb-binding protein 2) genes, and miRNAs including miR-101, miR-145-5p, miR-494, and small nucleolar RNA U6, were purchased from Applied Biosystems.
Transfection
Primary airway epithelial cells were grown on Transwell permeable supports (Corning Costar) to terminal differentiation with transepithelial resistance greater than 500 V on 24-well plates. Epithelial cells grown to confluence were mounted in modified Ussing chambers. Short-circuit current (Isc) was obtained with an epithelial voltage clamp as described previously (34) . Briefly, the mucosal bathing solution was changed to a low Cl -solution containing 1.2 mM NaCl, 115 mM sodium gluconate, plus 100 mM amiloride followed by addition of agonists (20 mM forskolin, and/or 10 mM ivacaftor) to the mucosal surface. CFTR inhibitor 172 (CFTR inh -172) (10 mM; Sigma-Aldrich) was added to the bathing solution at the conclusion of each experiment to block CFTR-dependent Isc.
Regulatory Approval
All studies involving human subjects or material were reviewed and approved by the University of Alabama Institutional Review Board (Protocols X081204008, F070813009).
Statistical Analysis
Data comparisons were performed with SAS version 9.4 (SAS Institute) and GraphPad Prism version 7.1 (GraphPad Software Inc.).
In vitro experiments with primary airway epithelia studies utilized biospecimens collected from multiple donors (n = 4 CF and n = 5 non-CF biological replicates), 
Results
Identification of TGF-b-and CFTR-Relevant miRNAs
We determined the expression profile of a panel of relevant CFTR-specific miRNAs in human BAL fluid and primary airway epithelial cells (AECs). Before in vitro assays, we computationally screened miRNAs predicted to regulate the CFTR gene (TargetScan 7.1; see Figure E1 in the online supplement), in which three candidate miRNAs (miR-101, miR-145, and miR-494) exhibited direct, well-conserved binding sites on the 39-UTR of CFTR mRNA across species that had supportive literature reporting significance in CF and/or influence on CFTR transcript stability (20) (21) (22) . Identification of these CFTR-specific miRNAs was further confirmed by two other popular prediction algorithms (miRWalk and miRanda; Table E1 ). miR-145 was emphasized for its direct relevance to TGF-b-associated respiratory disease and established binding site of CFTR mRNA (40) (41) (42) (43) .
To confirm whether miR-145 directly binds to the 39-UTR of the human CFTR transcript (as shown in Figure 1A) , we transfected CFBE cell lines with a commercially available CFTR 39-UTR reporter construct together with a miR-145 mimic or a negative control precursor miRNA. When the reporter plasmid containing the CFTR 39-UTR cloned upstream of its promoter region is bound by the specific miRNA, luminescence is suppressed. Addition of the miR-145 mimic to CFBE cells significantly decreased luciferase reporter activity by more than 50% (P , 0.01), demonstrating direct binding of miR-145 to the human CFTR 39-UTR ( Figure 1B) .
Expression of miRNA-145 in Airway Epithelia
We first evaluated miRNA expression profiling in RNA samples isolated from human AECs to quantify relevance to human disease. The extraction method included all small RNAs including miRNAs.
For miRNA expression screening in primary epithelial cells, we examined CFTR-specific miRNAs (miR-145, miR-101, and miR-494) and identified significantly increased miR-145 (approximately 10-fold) in F508del CF primary AECs ( Figure 1C) . Evaluation of human bronchial epithelial cell lines similarly demonstrated a twofold increase in miR-145 expression in the F508del CFBE cell line compared with wild-type CFBE cells ( Figure 1D ). These expression profiles indicate the relevance of increased miR-145 expression in CF epithelia.
Expression of miR-145 in CF BAL Fluid Exosomes
To confirm the relevance of miR-145 to CF pulmonary disease, we isolated exosomes from CF and non-CF BAL fluid. miRNA qPCR assays identified increased miR-145 expression (.fivefold) in CF BAL samples compared with the non-CF control group ( Figure 2A) . As TGF-b is a major stimulus of miR-145 in non-CF disease, we also measured TGF-b and a representative downstream signal (PAI-1) by qPCR. TGF-b mRNA expression was increased threefold in CF BAL exosomes ( Figure 2B ) and TGF-b signaling (PAI-1) was upregulated .10-fold compared with non-CF samples ( Figure 2C ).
TGF-b Stimulates miR-145 Expression in Airway Epithelial Cells
To evaluate the source of increased miR-145 in CF epithelia, we tested the idea that TGF-b stimulates miR-145 expression in AECs. Under basal conditions, CF primary AECs manifest a threefold increase in both TGF-b transcription and signaling (represented by PAI-1 expression) compared with non-CF cells ( Figure 2D ). Previous reports have suggested that TGF-b exposure upregulates miR-145 expression in smooth muscle and fibroblasts (23, 44, 45) , but no previous studies have examined the miR-145 response to TGF-b in airway epithelial cells. Exogenous TGF-b (5 ng/ml) added to the basolateral medium of non-CF and CF primary AECs increased miR-145 expression more than twofold ( Figure 2E ). These data suggest that TGF-b stimulation upregulates miR-145 transcription in airway epithelia.
TGF-b Inhibits CFTR Synthesis and Function in Airway Epithelia
To establish a signaling pathway connecting TGF-b, miR-145, and CFTR function we first determined whether TGF-b can alter CFTR expression. Exogenous TGF-b added to basolateral medium of non-CF and CF primary AEC monolayers grown on Transwell filters at the air-liquid interface for 24 hours significantly diminished CFTR transcript and protein levels ( Figures 3A-3C ). These reductions in CFTR mRNA and protein levels after TGF-b stimulation led to representative reduction in both wild-type and F508del CFTR channel function in airway epithelia evaluated by short-circuit current (Isc) measurement in modified Ussing chambers ( Figures 3D and 3E ). This functional assay measured CFTR ion channel activity in which CFTR Isc was stimulated with the cyclic AMP agonist forskolin and then potentiated (CF cells) with ivacaftor (VX-770), followed by functional inhibition with CFTR inh -172.
miR-145 Downregulates CFTR in Primary Airway Epithelial Cells
We then tested the hypothesis that miR-145 mediates TGF-b inhibition of CFTR synthesis and function in airway epithelia. The CFTR gene harbors highly conserved nucleotide sequences (7-8 nucleotides long through 39-UTR) that are specifically bound by miR-145 ( Figure 1A ), blocking CFTR mRNA translation or stability. Binding of miRNA-145 to the CFTR 39-UTR has been reported previously as well as by our assays ( Figure 1B ) (19, 21, 22) , but its impact on CFTR biological function in primary airway epithelia remains suboptimally defined. Non-CF primary polarized AECs were transfected basolaterally with a 20 nM concentration of a miR-145 mimic (double-stranded RNAs that mimic endogenous precursor of mature miR-145), or miR-145 negative control for 48 hours. Overexpression of miR-145 by mimics led to a significant decrease in CFTR mRNA ( Figure 4A ) and protein levels ( Figure 4B ) (P , 0.05). The functional consequence of the miR-145 mimic on ion transport is shown in Figure 4C .
Anti-miR-145 Attenuates TGF-b Signaling in Airway Epithelia
As TGF-b increased miR-145 expression in airway epithelial cells, we hypothesized that a miR-145-specific antagomir would interrupt TGF-b signaling. This miR-145 antagonist is a single-stranded RNA-based oligonucleotide designed to bind specifically to miR-145 and inhibit miRNA-induced silencing activity. To assess this novel TGF-b-inhibitory strategy, non-CF primary polarized AECs were transfected with a miR-145 antagonist and TGF-b for 24 hours. We then examined a number of TGFb pathway-specific genes including BMP2 and LTBP2. Inhibition of miR-145 significantly downregulated the expression of BMP2 and LTBP2 in primary AECs ( Figures 5A and 5B), indicating that miR-145 antagonism has broad applicability to diminish TGF-b signaling in airway epithelia. (Figures 5E and 5F ). These data demonstrate a significant benefit for miR-145 antagonists to reverse TGF-b inhibition of wild-type CFTR. A topic relevant to current CFTR therapeutic development is the impact of miR-145 on CFTR correction. F508del CFTR primary AECs were treated with 3 mM lumacaftor (VX-809) and TGF-b for 24 hours. First, we replicated previous reports of TGF-b inhibition of CFTR correction (9) , with significant reductions in CFTR channel activity in CF primary AECs ( Figure 6A ). In lumacaftor-treated F508del CF AECs, miR-145 mimics Figure 6B ), implying that miR-145 mediates TGF-b downregulation of CFTR, likely through transcriptional instability that decreases the available substrate for lumacaftor correction. Figures 7C and 7D) .
As CF primary polarized cells have elevated TGF-b signaling and miR-145 expression at baseline ( Figures 1C and 2A) , we then examined the benefit of miR-145 antagonism in CF AECs treated with lumacaftor only (e.g., in the absence of exogenous TGF-b stimulation). Lumacaftor-corrected CF primary AECs were exposed to miR-145 antagonists or a miRNA control for 48 hours. miR-145 antagonism significantly improved lumacaftor benefit in CF AECs, augmenting Together, these data indicate the potential benefit of miR-145 antagonists to improve CFTR corrector benefit in CF epithelia, in both the setting of increased TGF-b signaling and under basal CF conditions.
Discussion
This study is the first to identify miR-145 as a targetable mechanism linking TGF-b signaling to diminished CFTR function with direct consequences on CFTR modulator strategies. TGF-b is a wellestablished genetic modifier of CF lung disease (3), with more profound modifier effects in the setting of partial CFTR function or adverse environmental exposure (5). We and others (9, 10) have previously shown a relationship between TGF-b exposure and CFTR functional inhibition, and the present findings now provide a direct mechanism for this response. miR-145 has been identified previously as a significant modifier of TGF-b pathobiology in pulmonary hypertension and fibrosis with specific relevance to smooth muscle and myofibroblast phenotype (23, 43, 44, 46, 47) , and now we have identified a similar role for this miRNA in CF airway epithelia. With rapidly expanding knowledge of miRNA (40, 41, 48) and the reported preclinical success utilizing miR-145 in animal models of asthma and pulmonary hypertension (46, 49, 50) , manipulation of miR-145 may offer a novel avenue to augment the in vivo CFTR modulator response in the setting of TGF-b-associated lung pathology. Our results extend previous miRNA reports (20) (21) (22) in CF to now identify miR-145 as a targetable obstacle limiting the efficacy of F508del CFTR correction in the setting of increased TGF-b signaling.
Our results provide a mechanism through which TGF-b inhibits CFTR synthesis and function in non-CF cells and suppresses lumacaftor correction of F508del CFTR in CF epithelia ( Figure 9 ). As an endogenous biomolecule, miR-145 regulates many gene products including CFTR. TGF-b upregulates miR-145 that binds the 39-UTR of CFTR mRNA to decrease transcript stability, block translation, or both. In the setting of CFTR modulation, miR-145 reduces the amount of mutant F508del CFTR substrate available for correction. In acquired CFTR dysfunction in non-CF disease, miR-145 limits CFTR protein translation to reduce the number of available channels to facilitate ion transport. Antagonism to miR-145 restores F508del CFTR correction and wild-type CFTR function, suggesting a general applicability to improving CFTR modulator strategies across genotypes.
Our study focused on miR-145 to mediate TGF-b pathobiology in CF and limit CFTR correction because this miRNA uniquely overlapped computationally predicted miRNA data sets for TGF-b and CFTR (TargetScan miRNA target prediction tool, release 7.1). Among CFTR-relevant miRNAs, miR-101, miR-145, and miR-494 are commonly reported (15, 19, 20, 22) . The data set for TGF-b-relevant miRNA in lung disease is broader, but similarly includes miR-145 among many others (44, 45, 51, 52) . We then evaluated human CF BAL fluid and airway epithelia for expression of these miRNAs, of which miR-145 was found to be robustly increased. Our concomitant findings of increased TGF-b and downstream signal PAI-1 suggest that increased TGF-b signaling in CF cells is one stimulus for this increased miR-145 expression. These initial computational predictions and screening measures suggest miR-145 is available for TGF-b manipulation in lung tissue and may contribute to CFTR dysfunction in respiratory epithelia. miR-145 regulation by TGF-b has not been studied extensively before in CF disease. Our data now provide multiple contributions to this literature. First, we show that miR-145 is significantly increased in CF primary polarized primary epithelia and BAL exosomes compared with non-CF. Even under basal conditions, the miRNA milieu is altered in primary CF cells. Our data in primary airway epithelial cells suggest that this elevation is at least partially secondary to increased TGF-b expression and signaling that we have previously identified in CF BAL fluid and lung tissue (36, 53) . The increased expression of miR-145 in CF epithelia may limit the efficacy of mutant CFTR correction, with this hypothesis confirmed by the efficacy of miR-145 antagonism to augment CFTR modulation even in the absence of exogenous TGF-b stimulation.
An additional important finding is that TGF-b stimulation further increases miR-145 expression in both CF and non-CF airway epithelia. Our findings suggest an important application and mechanism for TGF-b to contribute to acquired CFTR dysfunction in non-CF respiratory disease. These data indicate that increased TGF-b levels in CF may be an obstacle to CFTR restoration and provides a mechanistic rationale to pursue nuanced TGF-b signaling antagonists as a possible adjunct to CFTR modulator development. Beyond direct binding to the CFTR mRNA 39-UTR, both miR-145 and TGF-b may have additional secondary effects on CFTR promoter activity or protein stability. One relevant example of this secondary regulation is miR-145 inhibition of KLF4 (Kruppel-like factor 4), which influences cellular response to injury and differentiation (23, 41, 43, 54, 55) . Although we have focused specifically on miR-145 antagonism, application of alternative TGF-b inhibitory strategies may also diminish miR-145 expression and preserve CFTR restoration.
We have focused on F508del CFTR correction for our studies as this is the most common mutation, with 90% of patients with CF having at least one F508del mutation and more than 50% of patients with CF being homozygous for this mutation (1, 2, 56) . Although F508del correctors have generated in vitro promise, the in vivo response has not been as robust as desired (24, 26, 57) . Our previous data on increased TGF-b in CF (36, 53, 58, 59) suggest that some of the suboptimal in vivo results of lumacaftor may be influenced by increased TGF-b signaling in CF lungs. The present findings in both non-CF and CF primary epithelia reinforce this concern and suggest that modulator efficacy should be evaluated in the setting of CF pulmonary conditions that are known to influence CFTR stability. Although the current data emphasize downregulation of F508del correction, the mechanism of miRNA-inhibited transcript stability suggests that suppression of CFTR-directed therapeutics may affect next-generation modulators and additional genotypes. Our data have the overt limitation of utilizing in vitro conditions rather than an in vivo model. Although the study of CFTR modulator response in primary polarized airway epithelial cells has successfully laid the foundation for CFTR modulator development (27, 35) , pertinent questions remain concerning the in vivo consequence of increased TGF-b stimulation on CFTR expression in airway epithelia, including a threshold definition separating pathophysiological TGF-b conditions from baseline. The dose of 5 ng/ml is commonly utilized to replicate TGF-b-stimulated conditions for in vitro studies (60) (61) (62) (63) and is consistent with the dose-finding range of 0.1-10 ng/ml that we detected in our previous report (9) . Our previous studies of increased TGF-b in CF BAL fluid (36) and circulating plasma (58) support this dose administration. An important next step in this field will be to quantify the consequences of TGF-b stimulation on CFTR function in vivo.
In summary, our article reports a plausible, targetable miRNA mechanism linking increased TGF-b signaling to diminished F508del CFTR correction in CF airway epithelia. Beyond the important context of CFTR therapeutics, our results provide an applicable mechanism for TGFb-derived acquired CFTR deficiency in non-CF disease. We have identified miR-145 as the most likely miRNA to connect these two pathways and completed a series of experiments to demonstrate the necessity and sufficiency of miR-145 to mediate CFTR inhibition in airway epithelia. Specifically, miR-145 alone diminishes CFTR function and limits the potency of F508del CFTR correction in non-CF and CF airway epithelia. Relatedly, miR-145 antagonism reverses TGF-b inhibition of CFTR function and enhances lumacaftor/ivacaftor CFTR modulation in TGF-b-exposed epithelia. These findings have direct relevance to advancing the in vivo benefit of CFTR modulators with broad application to studies of acquired CFTR dysfunction in TGF-b-associated respiratory disease. n Author disclosures are available with the text of this article at www.atsjournals.org.
